Salim Syed

Salim and his three-person team (including 2 PhDs and 1 MD) are known for their in-depth reports, quick yet insightful notes and client-centric / commercial approach to covering the biotechnology sector (both Large-cap and SMID-cap Biotechnology). The team has recently expanded its oncology coverage and separately written over 700-pages on new stocks, for specialists and generalists alike. In addition to product, the team remains hyper-focused on servicing clients with an every-client-and-every-question-matters approach with quick turnaround times, and provides corporate access around critical catalysts.

The biotech team hosted Mizuho’s 5th Annual Therapeutics Expert Seminar with over 200 attendees, and Mizuho’s 2nd Annual Neuroscience Summit in Boston. Salim’s team held multiple investor group zoom webinars on the space and single-stock frameworks (e.g., BBIO, PCVX, CYTK). Salim’s team also held Mizuho’s 5th Annual Diwali Biotech investor event in NYC. In addition, through the year, his team held various KOL calls and NDRs.

Salim Syed joined Mizuho in February 2016 as a senior analyst based in New York, covering both Large-cap and SMID-cap Biotechnology. Since joining Mizuho, Salim has twice been named a first place Institutional Investor All-America Research Team Rising Star for Large-cap Biotechnology stocks and has consistently appeared in the survey for both Large-cap Biotechnology and SMID-cap Biotechnology. Prior to Mizuho, Salim spent over five years as a member of Evercore ISI’s Institutional Investor All-America Research Team, First-Team in the Biotechnology and Major Pharmaceuticals.  Prior to Evercore ISI, Salim spent over four years at Morgan Stanley as an investment banker. He holds a BBA from the University of Michigan.